GANT61 suppresses proliferation and induces apoptosis in ALK-Positive anaplastic large cell lymphoma via modulating the Hh-PIK3IP1-Akt signaling axis
Annals of Hematology · 2026
DOI: 10.1007/s00277-026-06827-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Hongyuan Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China. Hauptthemen laut MEDLINE: Lymphoma, Large-Cell, Anaplastic, Apoptosis, Pyrimidines, Anaplastic Lymphoma Kinase. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jingjing Gao, Shengquan Liu, Xiongpeng Zhu.
Abstract (Originalsprache)
This study aimed to initially characterize the effects of GANT61, a Hedgehog (Hh) signaling pathway inhibitor, on the biological behaviors of ALK-positive anaplastic large cell lymphoma (ALK + ALCL) cell lines and explore its underlying mechanisms. Cell proliferation was determined by CCK-8 assays. Cell cycle distribution and apoptotic rates were assessed by flow cytometry. Differential gene analysis and pathway enrichment studies were conducted using datasets from the GEO database with R packages. Protein expression levels of apoptosis-related markers (Bcl-2, Bax, caspase-3, cleaved caspase-3) and signaling molecules (Gli1, PIK3IP1, Akt, phosphorylated Akt) were quantitatively examined by western blotting. Corresponding mRNA levels were quantified by qRT-PCR. GANT61 treatment inhibited proliferation in a dose- and time-dependent manner, induced cell cycle arrest, and promoted apoptosis in ALK + ALCL cell lines. Notably, PIK3IP1 expression was markedly reduced compared with normal lymphocyte controls, while GAS1 expression showed significant upregulation in ALK + ALCL cell lines. Gene Set Enrichment Analysis (GSEA) demonstrated significant enrichment of the PI3K/Akt and Hh signaling pathways. Mechanistically, GANT61 upregulated PIK3IP1 while downregulating both Gli1 protein level and Akt phosphorylation. The Gli-targeting agent GANT61 may inhibit ALK + ALCL cell growth, trigger cell cycle arrest and induce apoptosis through Gli1 inhibition, potentially leading to PIK3IP1 upregulation and subsequent attenuation of PI3K/Akt pathway activity. These findings indicate that the Hh-PIK3IP1-Akt signaling axis may participate in ALK + ALCL tumorigenesis, showing that conventional target drugs can be employed for ALK + ALCL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
- Fujian Medical University, Fuzhou, China.
- Department of Blood Transfusion, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
- Department of Pathology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
- Department of Hematology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China. xiongpengzhu@163.com.
Förderung
- Jingjing Gao
- Shengquan Liu
- Xiongpeng Zhu
Zitieren
APA
Chen, H., Gao, J., Li, C., Han, Y., Liu, S., & Zhu, X. (2026). GANT61 suppresses proliferation and induces apoptosis in ALK-Positive anaplastic large cell lymphoma via modulating the Hh-PIK3IP1-Akt signaling axis. Annals of Hematology. https://doi.org/10.1007/s00277-026-06827-2
Vancouver
Chen H, Gao J, Li C, Han Y, Liu S, Zhu X. GANT61 suppresses proliferation and induces apoptosis in ALK-Positive anaplastic large cell lymphoma via modulating the Hh-PIK3IP1-Akt signaling axis. Annals of Hematology. 2026. doi:10.1007/s00277-026-06827-2
BibTeX
@article{Chen2026,
author = {Chen, Hongyuan and Gao, Jingjing and Li, Chuntuan and Han, Yan and Liu, Shengquan and Zhu, Xiongpeng},
title = {GANT61 suppresses proliferation and induces apoptosis in ALK-Positive anaplastic large cell lymphoma via modulating the Hh-PIK3IP1-Akt signaling axis},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-06827-2}
}
EUVIMED